Latest news
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 13:53:58 GMTInnate Pharma S.A. and Swedish Orphan Biovitrum AB Enter Licensing Agreement for Lacutamab in T-Cell Lymphoma - marketscreener.commarketscreener.com · Mon, 10 Aug 2026 11:52:53 GMTSobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 11:13:48 GMTIPHA Looks 1053.3% Overvalued on GF Value™ - GuruFocusGuruFocus · Mon, 10 Aug 2026 10:23:23 GMTSobi adds rare lymphoma drug with $580m Innate tie-up - pharmaphorumpharmaphorum · Mon, 10 Aug 2026 10:15:01 GMTInnate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push - stocktitan.netstocktitan.net · Mon, 10 Aug 2026 10:05:10 GMTSobi, Innate sign $580M pact to propel lymphoma drug through Phase III - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 09:22:30 GMTInnate Pharma advances lacutamab to Phase 3 and appoints CMO - World Business OutlookWorld Business Outlook · Mon, 10 Aug 2026 09:00:15 GMT